Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays.
Cerebrospinal fluid
Lipoproteins
RT-QuIC
Seed amplification assays
α-synuclein
Journal
Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
26
08
2022
accepted:
12
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Aggregation of α-synuclein (α-syn) is a prominent feature of Parkinson's disease (PD) and other synucleinopathies. Currently, α-syn seed amplification assays (SAAs) using cerebrospinal fluid (CSF) represent the most promising diagnostic tools for synucleinopathies. However, CSF itself contains several compounds that can modulate the aggregation of α-syn in a patient-dependent manner, potentially undermining unoptimized α-syn SAAs and preventing seed quantification. In this study, we characterized the inhibitory effect of CSF milieu on detection of α-syn aggregates by means of CSF fractionation, mass spectrometry, immunoassays, transmission electron microscopy, solution nuclear magnetic resonance spectroscopy, a highly accurate and standardized diagnostic SAA, and different in vitro aggregation conditions to evaluate spontaneous aggregation of α-syn. We found the high-molecular weight fraction of CSF (> 100,000 Da) to be highly inhibitory on α-syn aggregation and identified lipoproteins to be the main drivers of this effect. Direct interaction between lipoproteins and monomeric α-syn was not detected by solution nuclear magnetic resonance spectroscopy, on the other hand we observed lipoprotein-α-syn complexes by transmission electron microscopy. These observations are compatible with hypothesizing an interaction between lipoproteins and oligomeric/proto-fibrillary α-syn intermediates. We observed significantly slower amplification of α-syn seeds in PD CSF when lipoproteins were added to the reaction mix of diagnostic SAA. Additionally, we observed a decreased inhibition capacity of CSF on α-syn aggregation after immunodepleting ApoA1 and ApoE. Finally, we observed that CSF ApoA1 and ApoE levels significantly correlated with SAA kinetic parameters in n = 31 SAA-negative control CSF samples spiked with preformed α-syn aggregates. Our results describe a novel interaction between lipoproteins and α-syn aggregates that inhibits the formation of α-syn fibrils and could have relevant implications. Indeed, the donor-specific inhibition of CSF on α-syn aggregation explains the lack of quantitative results from analysis of SAA-derived kinetic parameters to date. Furthermore, our data show that lipoproteins are the main inhibitory components of CSF, suggesting that lipoprotein concentration measurements could be incorporated into data analysis models to eliminate the confounding effects of CSF milieu on α-syn quantification efforts.
Sections du résumé
BACKGROUND
Aggregation of α-synuclein (α-syn) is a prominent feature of Parkinson's disease (PD) and other synucleinopathies. Currently, α-syn seed amplification assays (SAAs) using cerebrospinal fluid (CSF) represent the most promising diagnostic tools for synucleinopathies. However, CSF itself contains several compounds that can modulate the aggregation of α-syn in a patient-dependent manner, potentially undermining unoptimized α-syn SAAs and preventing seed quantification.
METHODS
In this study, we characterized the inhibitory effect of CSF milieu on detection of α-syn aggregates by means of CSF fractionation, mass spectrometry, immunoassays, transmission electron microscopy, solution nuclear magnetic resonance spectroscopy, a highly accurate and standardized diagnostic SAA, and different in vitro aggregation conditions to evaluate spontaneous aggregation of α-syn.
RESULTS
We found the high-molecular weight fraction of CSF (> 100,000 Da) to be highly inhibitory on α-syn aggregation and identified lipoproteins to be the main drivers of this effect. Direct interaction between lipoproteins and monomeric α-syn was not detected by solution nuclear magnetic resonance spectroscopy, on the other hand we observed lipoprotein-α-syn complexes by transmission electron microscopy. These observations are compatible with hypothesizing an interaction between lipoproteins and oligomeric/proto-fibrillary α-syn intermediates. We observed significantly slower amplification of α-syn seeds in PD CSF when lipoproteins were added to the reaction mix of diagnostic SAA. Additionally, we observed a decreased inhibition capacity of CSF on α-syn aggregation after immunodepleting ApoA1 and ApoE. Finally, we observed that CSF ApoA1 and ApoE levels significantly correlated with SAA kinetic parameters in n = 31 SAA-negative control CSF samples spiked with preformed α-syn aggregates.
CONCLUSIONS
Our results describe a novel interaction between lipoproteins and α-syn aggregates that inhibits the formation of α-syn fibrils and could have relevant implications. Indeed, the donor-specific inhibition of CSF on α-syn aggregation explains the lack of quantitative results from analysis of SAA-derived kinetic parameters to date. Furthermore, our data show that lipoproteins are the main inhibitory components of CSF, suggesting that lipoprotein concentration measurements could be incorporated into data analysis models to eliminate the confounding effects of CSF milieu on α-syn quantification efforts.
Identifiants
pubmed: 37005644
doi: 10.1186/s13024-023-00613-8
pii: 10.1186/s13024-023-00613-8
pmc: PMC10068178
doi:
Substances chimiques
alpha-Synuclein
0
Lipoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Subventions
Organisme : Parkinson's Disease Foundation
ID : PF-PRF-934916
Pays : United States
Organisme : Associazione Italiana Ricerca Alzheimer
ID : AGYR2020
Organisme : HORIZON EUROPE Marie Sklodowska-Curie Actions
ID : 860197 - MIRIADE
Informations de copyright
© 2023. The Author(s).
Références
Neurology. 2009 Dec 1;73(22):1914-22
pubmed: 19949037
Cholesterol. 2012;2012:292598
pubmed: 23119149
J Phys Chem B. 2019 May 23;123(20):4380-4386
pubmed: 31034772
Mov Disord. 2021 Oct;36(10):2444-2446
pubmed: 34236720
Chem Commun (Camb). 2018 Jul 14;54(55):7601-7604
pubmed: 29767190
Front Neurosci. 2021 Mar 31;15:647783
pubmed: 33867925
Nat Protoc. 2023 Apr;18(4):1179-1196
pubmed: 36653527
Acta Neuropathol. 2020 Jul;140(1):49-62
pubmed: 32342188
Sci Adv. 2021 May 14;7(20):
pubmed: 33990334
Sci Rep. 2020 Jun 4;10(1):9106
pubmed: 32499567
Methods Enzymol. 2006;413:326-44
pubmed: 17046404
Protein Expr Purif. 2005 Jul;42(1):173-7
pubmed: 15939304
Lancet Neurol. 2021 Mar;20(3):203-212
pubmed: 33609478
Methods Mol Biol. 2019;1948:35-44
pubmed: 30771168
J Mol Neurosci. 2017 Oct;63(2):165-172
pubmed: 28887769
Acta Neuropathol Commun. 2021 Apr 7;9(1):62
pubmed: 33827706
J Biol Chem. 1987 Oct 15;262(29):14352-60
pubmed: 3115992
Mov Disord. 2019 Apr;34(4):536-544
pubmed: 30840785
Anal Chem. 2018 Oct 16;90(20):11962-11971
pubmed: 30211542
Nat Rev Neurol. 2020 Apr;16(4):185
pubmed: 32107475
Acta Neuropathol Commun. 2021 Nov 6;9(1):179
pubmed: 34742348
Mov Disord. 2015 May;30(6):805-12
pubmed: 25227208
Neurology. 2022 Aug 2;99(5):195-205
pubmed: 35914941
EMBO J. 1994 Apr 15;13(8):2007-12
pubmed: 8168497
Acta Neuropathol. 2022 Apr;143(4):453-469
pubmed: 35141810
Nutrients. 2019 Apr 21;11(4):
pubmed: 31010086
Acta Neuropathol. 2021 Dec;142(6):961-984
pubmed: 34514546
Ann Clin Transl Neurol. 2016 Aug 28;3(10):812-818
pubmed: 27752516
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1075-1088
pubmed: 34856754
J Lipid Res. 2001 Jul;42(7):1143-51
pubmed: 11441143
JAMA Neurol. 2017 Feb 01;74(2):163-172
pubmed: 27918765
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1305-15
pubmed: 27174096
Phys Chem Chem Phys. 2017 Jan 18;19(3):1839-1846
pubmed: 28000812
Acta Neuropathol Commun. 2018 Feb 9;6(1):7
pubmed: 29422107
Front Neurol. 2018 Jun 06;9:415
pubmed: 29928254
Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15226-15235
pubmed: 31270237